NEWS & EVENTS
LATEST NEWS
Renaissance Pharma Limited, an Essential Pharma company, secures FDA Fast Track Designation and IND clearance for Daretabart (hu1418K322A) in high-risk neuroblastoma
FDA grants Fast Track Designation for Daretabart (hu1418K322A), recognising the significant unmet medical need in high-risk neuroblastoma and enabling access to accelerated and...
Essential Pharma strengthens rare disease portfolio with acquisition of Ventavis® (iloprost trometamol) for adult primary pulmonary hypertension
Ventavis® is an established inhaled prostacyclin analogue for the treatment of primary pulmonary hypertension Acquisition reinforces Essential Pharma’s mission to serve the needs...
Essential Pharma appoints experienced pharmaceutical leaders Simon Ramsden and Rob Smith to leadership team
Egham, UK – 03 July 2025 – Essential Pharma (“Essential” or “the Company”), a global pharmaceutical company developing and delivering medicines for patients...
Essential Pharma strengthens Board with the appointment of Nicola Heffron as Non-Executive Director
Egham, UK – 25 June 2025 – Essential Pharma (“Essential” or “the Company”), a global pharmaceutical company developing and delivering medicines for patients...
Essential Pharma strengthens management team with appointment of Duncan Ferguson as Vice President, Commercial
Egham, UK – 6th May 2025 – Essential Pharma (“Essential” or “the Company”), a global pharmaceutical company developing and delivering medicines for patients...
Essential Pharma strengthens Board with the appointment of Jonathan Arnold as Non-Executive Director
Egham, UK – 30 April 2025 – Essential Pharma (“Essential” or “the Company”), a global pharmaceutical company developing and delivering medicines for patients...
Essential Pharma and Clinigen Expand Collaboration to Improve Patient Access in JAPAC
Agreement drives continued patient access to four important therapies in Japan and Korea Strengthens Essential Pharma and Clinigen’s combined market presence in the...
Essential Pharma announces €900 million recapitalisation through a Gyrus Capital Continuation Vehicle led by AlpInvest and new strategic financing from Sixth Street
Provides significant resources to build on diversified portfolio of established and rare disease medicines Egham, UK – 12 December 2024 – Essential Pharma...
Essential Pharma Announces the Appointment of Dr Liz Holmes as Chief Medical Officer
Newly established role at Essential Pharma further strengthens leadership team and supports global growth Dr Liz Holmes’ rare disease and oncology expertise to...
Essential Pharma launches campaign with International Health Partners to donate life-saving medicines to disaster-hit countries
Donations to help support over 30,000 patients in disaster-hit and vulnerable communities worldwide whilst reducing medicine waste Antibiotics, cardiovascular and mental health drugs...
Essential Pharma reaches agreement with AGC Biologics for late phase clinical manufacturing of its immunotherapy candidate for the treatment of high-risk neuroblastoma
Egham, UK and Copenhagen, Denmark – 11 June, 2024 – Essential Pharma, an international specialty pharma group focused on ensuring that patients have...
Essential Pharma Announces the Acquisition of Reminyl® (galantamine hydrobromide) Oral Capsules
Reminyl® is an established CNS brand for the symptomatic treatment of mild to moderately severe dementia of the Alzheimer type The acquisition ensures...
Essential Pharma acquires Renaissance Pharma Ltd with its clinical stage immunotherapy for the treatment of high-risk neuroblastoma
First development-stage asset to be added to the Essential Pharma portfolioand second product within rare disease Egham, UK – 9 April 2024 –...
Essential Pharma and AcedrA Biopharmaceuticals sign Distribution Agreement to commercialize essential medicines in the Middle East and North Africa region
Zug, Switzerland, Egham, UK and Riyadh, Saudi Arabia – March 26, 2024 – Essential Pharma, an international specialty pharma group focused on ensuring...
Essential Pharma acquires European rights to Colobreathe® (colistimethate sodium) from Teva
Colobreathe® is an inhaled antibiotic for the management of chronic Pseudomonas aeruginosa infections in cystic fibrosis patients The acquisition will help ensure continued...
Essential Pharma concludes Priadel pricing review under the VPAS with UK Department of Health
Zug, Switzerland & Egham, UK – 04 July 2023 – Essential Pharma, an international speciality pharma company focused on ensuring that patients have...
Essential Pharma appoints Lee Morley as Non-Executive Director to the Board
Zug, Switzerland & Egham, UK – 21 June 2023 – Essential Pharma, an international specialty pharma group focused on ensuring that patients have...
Essential Pharma Announces the Appointment of Emma Johnson as Chief Executive Officer
Zug, Switzerland & Egham, UK – 24 May 2023 – Essential Pharma, an international specialty pharma company focused on ensuring that patients have...
Essential Pharma statement on EC’s reform proposals for EU pharmaceutical regulation
Zug, Switzerland & Egham, UK – 22 May 2023 – Essential Pharma, an international specialty pharma group focused on ensuring that patients have...
UK marketing authorisations for IOPIDINE® (apraclonidine) fully transferred to Essential Pharma as change in UK NICE guidelines for glaucoma treatment expected to lead to increase in patients’ need for product
Recent change in NICE guidelines indicating laser surgery as first line therapy for glaucoma is expected to increase need for IOPIDINE to control...
Essential Pharma Announces the Acquisition of HALDOL®
HALDOL® is a first-generation ‘typical’ antipsychotic for the treatment of schizophrenia and some other psychiatric conditions The acquisition ensures access to this much-needed...
Essential Pharma strengthens its global operating platform in preparation for next stage of growth
Egham, UK – 25 August 2022 – Essential Pharma, an international speciality pharma group focused on maintaining access to well-established, “at risk” products...
Essential Pharma makes strong progress in its ESG performance and now exceeds sector benchmarks
Egham, UK – 19 July, 2022 – Essential Pharma, an international speciality pharma group focused on maintaining access to well-established, “at risk” products...
Essential Pharma Appointments Soren Demin as Global Vice-President of Commercial and Head of Business Development
Egham, UK – 21 June, 2022 – Essential Pharma, an international specialty pharma group focused on maintaining access to well-established, “at risk” products...
Essential Pharma Strengthens its Global Capabilities with New Appointments in Switzerland
Zug, Switzerland – 6 April, 2022 – Essential Pharma, an international speciality pharma group focused on maintaining access to well-established, “at risk” products...
Essential Pharma Appoints Andrew Webb as General Counsel
Egham, UK – 30 March 2022 – Essential Pharma, an international speciality pharma group focused on maintaining access to well-established, “at risk” products...
Essential Pharma significantly expands its Global Portfolio with product acquisitions for ocular and postpartum therapies from world leading pharmaceutical company
Zug, Switzerland – 16 December, 2021 – Essential Pharma, an international specialty pharma group focused on maintaining access to mature, well-established prescription pharmaceutical...
Essential Pharma completes two transactions with Rosemont Pharmaceuticals bringing into the portfolio several attractive niche products and streamlining the portfolio to pursue strategic growth ambition
Divestments of UK oral liquid products streamlines the portfolio and furthers Essential Pharma’s international growth strategy Acquired products are low volume, but essential...
Essential Pharma Appoints Georgina Mason as Human Resources Manager
Egham, UK – Essential Pharma, an international specialty pharma company focused on maintaining access to well-established, “at risk” products essential to patients across...
Essential Pharma Appoints Pharma and Healthcare Operations Expert Colin Brown As Chief Operating Officer
Colin has more than 35 years of experience in the pharmaceutical and consumer healthcare sectors, primarily focused on pharmaceutical development. In addition, he...
Essential Pharma Welcomes Swift and Successful Conclusion of CMA Priadel Inquiry
Follows Agreement on the Improved Pricing of Priadel with the Department of Health and Social Security Egham, UK – 18 December 2020 –...
Essential Pharma Appoints Ingvild Liborg As Chief Executive Officer
Essential Pharma, an international pharmaceutical generics company dedicated to supplying well-established, “at risk” products to patients across multiple therapeutic areas, announces the appointment...
Essential Pharma Appoints Ben Ash as Chief Financial Officer
Essential Pharma, an international generic pharmaceutical company dedicated to supplying well-established, “at risk” products to patients across multiple therapeutic areas, announces the appointment...
Essential Pharma Embarks on New Era of Growth Following Management Buy Out Supported by Gyrus Capital
Essential Pharma, an international pharmaceutical generics company dedicated to supplying well-established, “at risk” products to patients across multiple therapeutic areas, has been acquired...
LATEST Insights
Questions for Erica Fazakerley, Senior Supply Chain Planner 1. Can you tell us about your career journey and what led you to...
1. Can you tell us about your career journey and what led you to your current role at Essential Pharma? Back when I...
1. Can you tell us about your career journey and what led you to your current role at Essential Pharma? I graduated in...
1. Can you tell us about your career journey and what led you to your current role at Essential Pharma? After completing my...
With quality assurance being a critical aspect of pharmaceutical manufacturing and distribution, we sat down with John Scicluna, European Responsible Person at Essential...
Q&A with Emma Johnson, Chief Executive Officer, and Andrew Webb, General Counsel, on International Women’s Day
International Women’s Day In celebration of International Women’s Day, we sat down with our CEO, Emma Johnson, and Andrew Webb, General Counsel, to...
What is your role at Essential Pharma? I work in the Supply Chain function, as the Procurement & Sourcing Manager. My colleagues and...
